What is Retatrutide?

Retatrutide (LY3437943) is a synthetic, fatty-acid-modified peptide that activates the GIP, GLP-1 and glucagon receptors. It is supplied here as a lyophilised powder for in-vitro laboratory research only.

Last editorial review: 2026-09-18 · Part of the Retatrutide research hub

Definition and research designation

Retatrutide is the non-proprietary name for the investigational peptide first described in the literature as LY3437943. It belongs to the incretin-based class of peptides, meaning its backbone is derived from gut hormone sequences that act on the incretin receptors, and it is chemically modified so that it persists far longer in circulation than the native hormones it is based on.

Where older research peptides in this class engage a single receptor, retatrutide was designed from the outset to engage three: GIP, GLP-1 and glucagon. In published pharmacology work the molecule is characterised as a balanced tri-agonist rather than as a GLP-1 peptide with incidental secondary activity.

Peptide chemistry

The molecule is a single-chain peptide built on a GIP-like backbone with substitutions that stabilise the sequence against enzymatic degradation, together with a lipid (fatty acid) side chain. The lipid moiety promotes reversible binding to serum albumin, which is the standard structural strategy used to extend the half-life of incretin peptides so that weekly rather than daily administration becomes feasible in study designs.

For laboratory purposes the practical consequence of that chemistry is that retatrutide behaves like other albumin-binding peptide analogues: it is supplied freeze-dried, it is reconstituted in aqueous diluent before use, and it is sensitive to repeated freeze-thaw cycles and to prolonged exposure to light and warmth.

Why researchers study it

Interest in retatrutide comes from the fact that adding glucagon receptor activity to the two incretin receptors changes the pharmacological question being asked. GIP and GLP-1 receptor activity is associated in the literature with insulin secretion and appetite signalling, whereas glucagon receptor activity is associated with hepatic glucose handling and energy expenditure. Studying all three together is a different experiment from studying any one of them alone.

In practice that means retatrutide is most often used as a comparator or a probe: a way of asking what the triple-receptor profile adds relative to a dual agonist such as tirzepatide, or a single GLP-1 agonist such as semaglutide.

How it is supplied for research

Biovanta Research supplies retatrutide as a lyophilised powder in a sealed glass vial across eight strengths, each batch independently assayed by Janoshik Analytical with the certificate of analysis published before sale. The certificate is the document that lets a laboratory verify identity and purity against its own acceptance criteria before the vial is opened.

Every compound referenced in this library is supplied strictly for in-vitro laboratory research by qualified persons. None of the material below is medical advice, none of it describes human or veterinary use, and no dosing guidance is given.

Analytical verification

Identity and purity of a retatrutide batch are normally confirmed by a combination of reversed-phase HPLC, which separates the intact peptide from process-related impurities and degradation products, and mass spectrometry, which confirms the measured mass against the expected sequence mass. Neither technique alone is considered sufficient; together they are the standard basis for a certificate of analysis.

Any figure describing purity percentage, peak retention time or measured mass for a specific batch should be read from that batch’s certificate of analysis rather than assumed from the literature, because these values are determined per manufacturing run and are not fixed properties of the peptide in the abstract.

Choosing a model system

Because retatrutide activates three separate receptors, the choice of model system determines which part of its pharmacology an experiment can actually see. Recombinant cell lines expressing a single human receptor with a cAMP reporter are the standard first step, used to generate a clean, single-receptor concentration-response curve without interference from the other two targets.

Beyond single-receptor systems, primary islet preparations, hepatocyte cultures and rodent models are used in the published literature to probe integrated responses. Each has trade-offs: recombinant lines give clean pharmacology but limited physiological context, while primary and in-vivo systems give more physiological relevance at the cost of more variables to control for.

Development and regulatory status

Retatrutide remains an investigational compound. It has been reported in phase 2 clinical trials in the peer-reviewed literature, but it does not hold a marketing authorisation from the MHRA in the United Kingdom, the FDA in the United States, or any other medicines regulator, and no dosing or efficacy claims for human use can properly be made from the current record.

Researchers tracking the development programme should treat registered trial listings and peer-reviewed publications as the primary sources, and should be cautious of secondary summaries that present phase 2 findings as though they were confirmed, approved outcomes.

Strength of the current evidence

The receptor pharmacology of retatrutide is well described in peer-reviewed pharmacology literature. Clinical evidence is phase 2 stage and later, and remains investigational: retatrutide is not an approved medicine in the United Kingdom.

References

1. Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022 (PubMed)
2. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med, 2023 (DOI)
3. Registered retatrutide studies (ClinicalTrials.gov search listing)

Related Retatrutide research

• Mechanism of Action — How retatrutide engages the GIP, GLP-1 and glucagon receptors, and what that combined signalling is understood to do.
• Triple Receptor Agonism — What triple receptor agonism means in peptide design, and how balance between receptors is characterised.
• Published Research — An overview of the peer-reviewed retatrutide research record, from receptor pharmacology to phase 2 trials.
• Retatrutide vs Tirzepatide — Triple versus dual receptor agonism: how retatrutide and tirzepatide differ in receptor targets and study design.

Back to the Retatrutide research hub · Retatrutide research material · Certificates of analysis

Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.